Previous Article | Next Article ![]()
Journal of Clinical Microbiology, April 2009, p. 1252-1254, Vol. 47, No. 4
0095-1137/09/$08.00+0 doi:10.1128/JCM.02052-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
| CASE REPORT |

Service de Médicine Interne et des Maladies Infectieuses, Hôpital Robert Debré-CHU Reims, Reims, France,1 Laboratoire de Virologie Médicale et Moléculaire, EA4303/IFR53, CHU Reims, Hôpital Robert Debré, Reims, France,2 Laboratoire d'Anatomo-pathologie, Hôpital Robert Debré-CHU Reims, Avenue du Général Koenig, Reims, France,3 Laboratoire d'Hématologie, Hôpital Robert Debré-CHU Reims, Avenue du Général Koenig, Reims, France,4 Laboratoire de Cytogénétique, Hôpital Maison-Blanche-CHU Reims, Reims, France,5 Département d'Anesthésie-Réanimation, Hôpital Robert Debré-CHU Reims, Reims, France,6 Unité d'Immunopathologie, Département d'Immunologie Clinique, EA3963 Centre Hayem, Hôpital Saint Louis, 75010 Paris, France7
Received 22 October 2008/ Returned for modification 16 December 2008/ Accepted 28 January 2009
We report a case of Epstein-Barr virus (EBV) primo infection with the development of successive infectious mononucleosis, hemophagocytic lymphohistiocytosis, and B-cell lymphoproliferative disorder in a patient treated with azathioprine for Crohn's disease. This case report suggests that specific EBV-related clinical and virological management should be considered when treating a patient with inflammatory bowel disease with azathioprine.
Published ahead of print on 4 February 2009.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»